Please use this identifier to cite or link to this item:
Title: CoQ10 and Cognition a Review and Study Protocol for a 90-Day Randomized Controlled Trial Investigating the Cognitive Effects of Ubiquinol in the Healthy Elderly.
Austin Authors: Stough, Con;Nankivell, Madeleine;Camfield, David A;Perry, Naomi L;Pipingas, Andrew;Macpherson, Helen;Wesnes, Keith;Ou, Ruchong;Hare, David L ;de Haan, Judy;Head, Geoffrey;Lansjoen, Peter;Langsjoen, Alena;Tan, Brendan;Pase, Matthew P;King, Rebecca;Rowsell, Renee;Zwalf, Oliver;Rathner, Yossi;Cooke, Matthew;Rosenfeldt, Franklin
Affiliation: Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Faculty of Medicine, Dentistry, and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia
Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
Department of Health and Medical Sciences, Swinburne University of Technology, Melbourne, Victoria, Australia
Faculty of Health, Institute for Physical Activity and Nutrition, Deakin University, Geelong, Victoria, Australia
Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, Victoria, Australia
Wesnes Cognition Limited, Streatley on Thames, United Kingdom
Department of Psychology, Northumbria University, Newcastle, United Kingdom
Melbourne Dementia Research Centre, The Florey Institute for Neuroscience and Mental Health, Melbourne, Victoria, Australia
East Texas Medical Center and Trinity Mother Francis Hospital, Tyler, TX, United States
Issue Date: 29-May-2019 2019-05-29
Publication information: Frontiers in aging neuroscience 2019; 11: 103
Abstract: Introduction: With an aging population there is an important need for the development of effective treatments for the amelioration of cognitive decline. Multiple mechanisms underlie age-related cognitive decline including cerebrovascular disease, oxidative stress, reduced antioxidant capacity and mitochondrial dysfunction. CoQ10 is a novel treatment which has the potential to improve brain function in healthy elderly populations due to established beneficial effects on mitochondrial function, vascular function and oxidative stress. Methods and Analysis: We describe the protocol for a 90-day randomized controlled trial which examines the efficacy of Ubiquinol (200 mg/day) vs. placebo for the amelioration of cognitive decline in a healthy (non-demented) elderly sample, aged 60 years and over. The primary outcome is the effect of Ubiquinol at 90 days compared to baseline on CogTrack composite measures of cognition. Additional cognitive measures, as well as measures of cardiovascular function, oxidative stress, liver function and mood will also be monitored across 30-, 60- and 90- day time points. Data analyses will involve repeated measures analysis of variance (ANOVA). Discussion: This study will be the first of its kind to provide important clinical and mechanistic data regarding the efficacy of Ubiquinol as a treatment for age-related cognitive decline in the healthy elderly with important implications for productivity and quality of life within this age group. Clinical Trial Registration: The trial has been registered with the Australian and New Zealand Clinical Trials Registry (ANZCTRN12618001841268).
DOI: 10.3389/fnagi.2019.00103
PubMed URL: 31191293
ISSN: 1663-4365
Type: Journal Article
Subjects: Coenzyme Q10
cardiovascular function
cognitive decline
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.